Neurotrope BioSciences moves forward with novel Alzheimer's candidate
This article was originally published in Scrip
Executive Summary
Alzheimer's disease start up Neurotrope BioSciences is to proceed to Phase IIb studies of its lead product bryostatin after positive top-line safety data from a Phase IIa trial.